Bone scintigraphy findings in patients with recently diagnosed prostate adenocarcinoma: Relationship with the prostate specific antigen levels;Hallazgos de la gammagrafía ósea en pacientes con adenocarcinoma de próstata recién diagnosticado: Relación con los niveles de antígeno específico prostático

Revista Espanola de Medicina Nuclear

Volumn 19, Issue 6, 2000, Pages 409-415

  Ortega, A ^a   Alonso, J C ^a   Suarez M ^a   Dominguez P ^a   Almoguera, I ^a   Bittini, A ^a   Gomez A ^a   Martinez L ^a   Herranz, F ^a   Perez Vazquez J M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Bone scintigraphy; Prostate adenocarcinoma; Prostate specific antigen

Indexed keywords

METHYLPHOSPHONIC ACID; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; RADIATION DOSE; BLOOD; BONE TUMOR; CANCER STAGING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; RETROSPECTIVE STUDY; ROC CURVE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0034296790     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(00)71902-1     Document Type: Article

References (28)

1. Tumores malignos de próstata. En: Urología. Ed. L. Mejel Estévez, 1998.
2. Cumming J, Hacking N, Fairhurst J, Ackery D, Jenkins JD. Distribution of bony metastases in prostatic carcinoma. Br Journal of Urology 1990;66:411-4.
3. O'Donoghue JM, Rogers E, Grimes H, McCarthy P, Corcoran M, Bredin H, et al. A reappraisal of serial isotope bone scans in prostate cancer. Br J Radiology 66:672-6.
4. Koch MO, Miller DA, Butter R. Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis. Urology 1998;51:197.
5. Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976;121:431-34.
6. Siddall JK, Cooper EH, Newling DWW, Robinson MRG, Whelan P. An evaluation of the immunochemical measurement of prostatic acid phosphate and prostatic specific antigen in carcinoma of the prostate. Eur Urol 1986;12:123-30.
7. Hankaas S, Roervik J, Halvorsen OJ, Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol 1997;79:770-6.
8. Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, et al. The clinical value of prostate specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995;22:207-11.
9. Ruiz de la Roja JC, Llorente Abarca C, Romero Cagigal I, Paez Borda A, Fernández González I, Martín Oses E, et al. Is it possible to do without bone gammagraphy in the staging of prostatic cancer? Actas Urol Esp 1995;19:123-7.
10. Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 1994;17:432-6.
11. Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to al other clinical parameters. The Journal Urology 1991;145:318.
12. Levran Z, González JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995;75:778.
13. Rydh A, Tomic R, Tavelin B, Hietala SO, Damber JE. Predictive value of prostate specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer. Scand J Urol Nephrol 1999;33:89-93.
14. Spencer JA, Chng WJ, Hudson E, Boon AP, Whelan P. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Br J Radiol 1998;71:1130-5.
15. López M, Montes de Oca L, Bernardo N, Scorticati C Jr, Suárez P, Bencardino F, et al. Correlation between specific prostatic antigen and findings with total body bone scintigraphy. Arch Esp Urol 1996;49:953-5.
16. Amsellem D, Ogiez N, Salomon L, Chopin D, Abbou CC, Colombel M. Does PSA of less than 20 ng/ml exclude the diagnosis of metastatic prostate cancer? Prog Urol 1998;8:1018-21.
17. Morote J, Olona M, Villa J, Reig C, López MA, De Torres JA, et al. Can we do without bone gammagraphy in the staging of prostatic cancer? Actas Urol Esp 1992;16:487-9.
18. Miller PD, Eardley I, Kirby RS. Prostate Specific Antigen and Bone Scan correlation in the staging and monitoring of patients with prostatic cancer. British J Urology 1992;70:295-8.
19. Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998;33:376-81.
20. Lin K, Szabo Z, Chin BB, Chaid Civelek A. The 318 value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clinical Nuclear Medicine 1999;24:579-82.
21. Herranz Amo F, Díez Cordero JM, Verdú Tartajo F, Lledó García E, Subirá Castillón C, González Chamorro F, et al. Correlación entre el antígeno específico prostático, el grado tumoral y el estadio local con la gammagrafía ósea en el estadiaje de los pacientes con cáncer de próstata. Arch Esp Urol 1997;50:253-8.
22. Jacobson AF, Hammersmith SM. Valve of the baseline bone scan in patients with newly diagnosed prostate cancer and low prostate specific antigen level. J Nucl Med 1997;38:301.
23. Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer 1990;66:1009-16.
24. Rana A, Chisholm GD, Khand M, Sekharjit SS, Merrick MV, Elton RA. Patterns of bone metastasis and their prognostic significance in pataeants with carcinoma of the prostate. Br Journal Urology 1993;72:933-6.
25. Knudson G, Grinis G, López-Majano V, Sansí P, Targonski P, Rubenstein M, et al. Bone scan as a stratification variable in advanced prostate cancer. Cancer 1991;68:316-20.
26. Lobo G, Ladrón de Guevara D, Salgado G, Donoso G, Bagus F. Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival. Rev Med Chil 1999;127:181-8.
27. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940;112:138-49.
28. Batson OV. The role of the vertebral veins in metastatic processes. Ann Intern Med 1942;16:38-45.